Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The May 2000 Formulary monographs are linezolid, pneumococcal 7-valent conjugate vaccine, apomorphine, levobetaxolol HCl, mequinol 2% and tretinoin 0.1% topical solution. The DUE is on dexmedetomidine.
Get full access to this article
View all access options for this article.
References
1.
Tikosyn package literature. Pfizer Labs; November 1999.
2.
SedgwickM.L.Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am J Cardiol.1992; 69: 513–7.
3.
GwiltM.UK-68,798: A novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther.1991; 256: 318–24.
4.
KnilansT.K.Rate and concentration-dependent effects of UK-68,798, a potent new class III antiarrhythmic, on canine Purkinje fibre action potential duration and Vmax. Br J Pharmacol.1991; 103: 1568–72.
5.
SedgwickM.L.Effects of the new class III antiarrhythmic drug dofetilide on the atrial and ventricular intracardiac monophasic action potential in patients with angina pectoris. Eur Heart J.1995; 16: 1641–6.
6.
RasmussenH.S.Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol.1992; 20(suppl 2): S96–105.
7.
HoffmeisterK.M.Hemodynamic effects of antiarrhythmic compounds: Intrinsic effects and autonomic modulation. Am J Cardiol.1997; 80(8A): 24G–30G.
8.
MonteroM., SchmittC.Recording of transmembrane action potentials in chronic ischemic heart disease and dilated cardiomyopathy and the effects of the new class III antiarrhythmic agents D-sotalol and dofetilide. J Cardiovasc Pharmacol.1996; 27: 571–7.
9.
KobayashiY.Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias. J Cardiovasc Pharmacol.1997; 30: 367–73.
10.
SedgwickM.L.Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am J Cardiol.1992; 70: 1432–7.
11.
YuanS.Effect of dofetilide on cardiac repolarization in patients with ventricular tachycardia. A study using simultaneous monophasic action potential recordings from two sites in the right ventricle. Eur Heart J.1994; 15: 514–22.
12.
GemmillJ.D.A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers. Br J Clin Pharmacol.1991; 32: 429–32.
13.
SedgwickM.Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug. Br J Clin Pharmacol.1991; 31: 515–9.
14.
FalkR.H.Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol.1997; 29: 385–90.
15.
YangT.Negative chronotropic effect of a novel class III antiarrhythmic drug, UK-68,798, devoid of beta-blocking action on isolated guinea-pig atria. Br J Pharmacol.1991; 103: 1417–20.
16.
FrostL.Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Int J Cardiol.1997; 58: 135–40.
17.
TodtH.Differential effect of dofetilide on ventricular repolarization during steady state and during restitution in vivo. J Cardiovasc Pharmacol.1994; 24: 1010–3.
18.
DemolisJ-LInfluence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation.1996; 94: 1592–9.
19.
Le CozF.Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Clin Pharmacol Ther.1995; 57: 533–42.
20.
KoweyP.R.Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs. Am J Cardiol.1997; 80(8A): 16G–23G.
21.
LandeG.Dynamic analysis of dofetilide-induced changes in ventricular repolarization. Clin Pharmacol Ther.1998; 64: 312–21.
22.
LehmanR.Patients with long QT (QTc) interval are more likely to remain in sinus rhythm after one year treatment on dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) study [abstract]. American College of Cardiology 48th Annual Scientific Session; New Orleans, LA, March 7–10, 1999.
23.
SmithD.A.Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica.1992; 22: 709–19.
24.
ThamT.C.K.Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans. J Cardiovasc Pharmacol.1993; 21: 507–12.
25.
WalkerD.K.Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab Dispos.1996; 24: 447–55.
26.
SinghS.N.Oral dofetilide for conversion of patients with chronic atrial fibrillation or atrial flutter to normal sinus rhythm: A multicenter study [abstract]. J Am Coll Cardiol.1998; 31(suppl A): 884–1.
27.
DalrympleH.W.Maintenance of sinus rhythm by dofetilide improves quality of life. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) study [abstract]. Circulation.1998; 98: I13–4.
28.
GreenbaumR.Conversion of AF and maintenance of sinus rhythm by dofetilide [abstract]. Eur Heart J.1998; 19(suppl): P3682.
29.
SinghS.Re-establishment of sinus rhythm in subjects with atrial fibrillation/flutter improves exercise tolerance, preserves left ventricular function and decreases arrhythmia associated symptoms: The dofetilide SAFIRE-D study [abstract]. Eur Heart J.1998; 19(suppl): 661.
30.
SinghS.Restoration of sinus rhythm in subjects with atrial fibrillation improves exercise capacity. A SAFIRE-D substudy [abstract]. Circulation. 1998; (supp 1): 432.
31.
DIAMOND Study Group.Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: Rationale, design, and patient characteristics of the DIAMOND studies. Clin Cardiol.1997; 20: 704–10.
32.
SinghB.N.Antiarrhythmic drugs: A reorientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol.1998; 81(6A): 3D–13D.
33.
Anonymous.Pfizer dofetilide DIAMOND study shows 25% reduction in CHF hospitalization. The Pink Sheet.1997; 59(35): T&G–7.
34.
Torp-PedersenC.Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med.1999; 341: 857–65.
35.
KaberL.The Diamond Study Group. A clinical trial of dofetilide in patients with acute myocardial infarction and left ventricular dysfunction: The DIAMOND MI study [abstract]. Eur Heart J.1998; 19(suppl): P639.
36.
PedersenO.D.Dofetilide in the treatment of atrial fibrillation in patients with impaired left ventricular function [abstract]. Eur Heart J.1998; 19(suppl): 2037.
37.
PritchettE.L.C.Effect of dofetilide on survival in patients with supraventricular arrhythmias. Am Heart J.1999; 138: 994–7.
38.
NorgaardB.L.Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial. Am Heart J.1999; 137: 1062–9.
39.
SuttorpM.J.Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol.1992; 69: 417–9.
40.
CrijnsHJGMAtrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug. Eur Heart J.1994; 15: 1403–8.
41.
KurumaA.Use of intravenous dofetilide in atrial flutter with hemodynamic instability. Jpn Circ J.1996; 60: 67–9.
42.
BashirY.Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Am J Cardiol.1995; 76: 1040–4.
43.
ChoyA.M.J.Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol.1999; 34: 396–401.
44.
WebsterW.S.Teratogenic potential of almokalant, dofetilide, and d-sotalol: Drugs with potassium channel blocking activity. Teratology.1996; 53: 168–75.
